Compare Globus Medical Inc. Class A Common Stock (GMED) vs Keurig Dr Pepper Inc. Common Stock (KDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Keurig Dr Pepper Inc. Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Keurig Dr Pepper Inc. Common Stock trades at $33.5 (market cap $45.07B). The key difference: Keurig Dr Pepper Inc. Common Stock is far larger — about 4.4× Globus Medical Inc. Class A Common Stock's market cap, and Keurig Dr Pepper Inc. Common Stock pays a 2.78% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Keurig Dr Pepper Inc. Common Stock for 6 Days on average.
| GMED | KDP | |
|---|---|---|
Market Cap | $10.25B | $45.07B |
Volume | 1,059,528 | 9,868,301 |
Sector | Health | Consumer Staples |
52-Week High | $96.82 | $33.50 |
52-Week Low | $58.33 | $25.31 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $73.53B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Keurig Dr Pepper (KDP) trades at $32.66, down 0.27% today, with strong technical momentum showing bullish moving averages and key support at $32. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.57 beating expectations of $0.537, and maintains a healthy 49.39% gross margin. Recent news highlights the planned 2027 business split and beverage innovation pipeline as growth catalysts.
KDP presents a favorable investment case with 62% analyst buy ratings and a $37.75 consensus price target offering 15% upside. However, risks include elevated debt levels at 74.2% of market cap and potential execution challenges with the upcoming corporate restructuring. The stock's current valuation at 32.99 P/E requires continued earnings growth to justify further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Keurig Dr Pepper Inc. Common Stock
Keurig Dr Pepper produces and distributes coffee, soft drinks, juices, and other beverages. It also operates the Keurig single-serve coffee system.
Read more on KDP →
